203 related articles for article (PubMed ID: 22225786)
21. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
22. Mucinous micropapillary pattern in lung adenocarcinomas: a unique histology with genetic correlates.
Kamata T; Yoshida A; Shiraishi K; Furuta K; Kosuge T; Watanabe S; Asamura H; Tsuta K
Histopathology; 2016 Feb; 68(3):356-66. PubMed ID: 26109197
[TBL] [Abstract][Full Text] [Related]
23. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (Makimoto Y; Nabeshima K; Iwasaki H; Miyoshi T; Enatsu S; Shiraishi T; Iwasaki A; Shirakusa T; Kikuchi M
Histopathology; 2005 Jun; 46(6):677-84. PubMed ID: 15910599
[TBL] [Abstract][Full Text] [Related]
24. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.
Onozato ML; Kovach AE; Yeap BY; Morales-Oyarvide V; Klepeis VE; Tammireddy S; Heist RS; Mark EJ; Dias-Santagata D; Iafrate AJ; Yagi Y; Mino-Kenudson M
Am J Surg Pathol; 2013 Feb; 37(2):287-94. PubMed ID: 23095504
[TBL] [Abstract][Full Text] [Related]
25. Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells.
Lee HJ; Eom DW; Kang GH; Han SH; Cheon GJ; Oh HS; Han KH; Ahn HJ; Jang HJ; Han MS
Mod Pathol; 2013 Aug; 26(8):1123-31. PubMed ID: 23060121
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
[TBL] [Abstract][Full Text] [Related]
27. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
28. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary adenocarcinoma with micropapillary component: an immunohistochemical study. Case report.
Kuroda N; Hamauzu T; Toi M; Yamaoka K; Miyazaki E; Hiroi M; Nakata H; Taguchi H; Enzan H
APMIS; 2005; 113(7-8):550-4. PubMed ID: 16086826
[TBL] [Abstract][Full Text] [Related]
30. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of minimal micropapillary pattern in invasive lung adenocarcinoma: prognostic significance and survival outcomes.
Lee G; Lee HY; Jeong JY; Han J; Cha MJ; Lee KS; Kim J; Shim YM
Am J Surg Pathol; 2015 May; 39(5):660-6. PubMed ID: 25724001
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
33. Impact of GLUT1 and Ki-67 expression on early‑stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification.
Maki Y; Soh J; Ichimura K; Shien K; Furukawa M; Muraoka T; Tanaka N; Ueno T; Yamamoto H; Asano H; Tsukuda K; Toyooka S; Miyoshi S
Oncol Rep; 2013 Jan; 29(1):133-40. PubMed ID: 23076555
[TBL] [Abstract][Full Text] [Related]
34. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.
De Oliveira Duarte Achcar R; Nikiforova MN; Yousem SA
Am J Clin Pathol; 2009 May; 131(5):694-700. PubMed ID: 19369630
[TBL] [Abstract][Full Text] [Related]
35. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series.
Sánchez-Mora N; Presmanes MC; Monroy V; Moreno N; Lara-Martínez JM; Aladro MH; Alvarez-Fernández E
Hum Pathol; 2008 Mar; 39(3):324-30. PubMed ID: 18261622
[TBL] [Abstract][Full Text] [Related]
36. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
37. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.
Cha MJ; Lee HY; Lee KS; Jeong JY; Han J; Shim YM; Hwang HS
J Thorac Cardiovasc Surg; 2014 Mar; 147(3):921-928.e2. PubMed ID: 24199757
[TBL] [Abstract][Full Text] [Related]
38. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
39. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
40. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
